Difficulty: Medium
Average Score: 93%
Testbank
A client who is diagnosed multiple myeloma experiences decreased production of red blood cells (RBCs). Which prescribed medication should the nurse prepare to administer to increase the production of erythrocytes?
Correct answer
C
Rationale
Erythropoietin is the medication that stimulates the production of red blood cells in patients experiencing anemia, such as those with multiple myeloma.
Erythropoietin is a hormone that promotes erythropoiesis in the bone marrow, making it appropriate for addressing the decreased RBC production associated with multiple myeloma. This medication can help alleviate symptoms of anemia by increasing the number of circulating erythrocytes.
A: Filgrastim is a granulocyte colony-stimulating factor that primarily stimulates the production of white blood cells, not red blood cells, making it unsuitable for treating anemia in this context.
B: Pegfilgrastim is also a granulocyte colony-stimulating factor and is used to increase neutrophil counts after chemotherapy, which does not address the issue of decreased erythrocyte production in this patient.
D: Dexamethasone is a corticosteroid that may be used in multiple myeloma treatment but does not promote red blood cell production and is not indicated for the management of anemia in this case.
Erythropoietin is a hormone that promotes erythropoiesis in the bone marrow, making it appropriate for addressing the decreased RBC production associated with multiple myeloma. This medication can help alleviate symptoms of anemia by increasing the number of circulating erythrocytes.
A: Filgrastim is a granulocyte colony-stimulating factor that primarily stimulates the production of white blood cells, not red blood cells, making it unsuitable for treating anemia in this context.
B: Pegfilgrastim is also a granulocyte colony-stimulating factor and is used to increase neutrophil counts after chemotherapy, which does not address the issue of decreased erythrocyte production in this patient.
D: Dexamethasone is a corticosteroid that may be used in multiple myeloma treatment but does not promote red blood cell production and is not indicated for the management of anemia in this case.